Scientific Advisory Board

Meet our Advisors. Our Advisory Board Members are Global Experts and renowned Researchers &
Physicians that drive our mission forward.

Dr. Robert Bast

Dr. Robert Bast

Dr. Bast is best known for developing the CA125 test to be used as the first generally useful marker for monitoring the course of patients with epithelial ovarian cancer. Dr. Bast is Vice President for Translational Research at the UT M.D. Anderson Cancer Center. His office facilitates translation of new strategies, drugs and devices from laboratory to the clinic, as well as the movement of human material and data from the clinic to laboratory. Dr. Bast received his B.A. cum laude from Wesleyan University and his M.D. magna cum laude from Harvard Medical School.

Dr. Anil Sood

Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at the M. D. Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program.

Dr. Marta Crispens

Dr. Crispens is Professor and Director, Division of Gynecologic Oncology and the Chairman of Scientific Review Committee at Vanderbilt-Ingram Cancer Center. Dr. Crispens is a great advocate for patients impacted with ovarian cancer with extensive knowledge in effectively managing survivorship challenges.

Dr. Kunle Odunsi

Dr. Kunle Odunsi is an expert in immunotherapy and vaccine therapy for cancer, and is a nationally recognized physician-scientist with a deep knowledge of discovery and innovation in oncology. He pioneered the development of antigen-specific vaccine therapy and “next generation” adoptive T-cell immunotherapies to prolong remission rates in women with ovarian cancer.

Dr. Ursula Matulonis

Dr. Matulonis, is Chief and Director of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Dr. Matulonis also co-leads the Ovarian Cancer Program within the Dana-Farber/Harvard Cancer Center. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer. Dr. Matulonis has led several PARP inhibitor, immunotherapy, and combination trials for ovarian cancer in the United States and internationally.

Dr. Robert Coleman

Dr. Robert L. Coleman, is Chief Science Officer at McKesson Corporation. Dr. Coleman’s research interests include novel therapeutics for ovarian, uterine, and cervical cancer, clinical trial development and statistical design, surgical innovations, and graduate education. Dr. Coleman has authored or coauthored over 400 scientific publications, including over 188 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks.

Dr. Ronny Drapkin

Ronny Drapkin, MD, PhD, is the Franklin Payne Associate Professor of Pathology in Obstetrics & Gynecology at the University of Pennsylvania Perelman School of Medicine and Director of the Penn Ovarian Cancer Research Center. In addition, Dr. Drapkin is the Director of Gynecological Research at Penn Medicine’s Basser Center for BRCA. His research, teaching, and clinical activities focus on understanding the pathogenesis and genetic alterations involved in women’s cancers, with the intent to translate these important biological principles into clinically useful diagnostic and therapeutic tools.

Dr. Dineo Khabele

Dr. Khabele is a physician, surgeon, scientist, educator, advocate. She specializes in treating women diagnosed with ovarian and other gynecologic cancers and providing individualized and compassionate cancer care. She is also a productive scientist, and one of a few clinically active gynecologic oncologists who leads an ovarian cancer translational research program. Dr. Khabele is firmly committed to mentoring and training the next generation of physicians and scientists. As an advocate, Dr. Khabele is dedicated to raising awareness about women’s cancers and cancer health disparities.

Dr. Anirban Maitra

Pre-eminent pancreatic cancer expert Dr. Maitra is the first co-director and scientific director of MD Anderson’s Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research. Dr. Maitra came from Johns Hopkins University School of Medicine in Baltimore, where he was a professor of pathology and oncology at the Sol Goldman Pancreatic Cancer Research Center and an affiliate faculty member of the McKusick-Nathans Institute of Genetic Medicine.

Dr.Jaydip Bhaumik

Ovarcome Chief Advisor – Tata medical Center, Kolkata
DGO, MS, DNB, FRCOG, MPH
Senior Consultant, Gynecology, Tata Medical Center, Kolkata, India

Dr. Dennis Chi

Dr. Dennis Chi is Ronald O. Perelman Chair in Gynecologic Surgery; Deputy Chief, Gynecology Service, and Head of Ovarian Cancer Surgery at the Memorial Sloan Kettering Cancer Center. He has devoted his career to caring for women with cancerous and noncancerous gynecologic diseases, including cervical cancer, uterine cancer, ovarian cancer, and vulvar cancer.

Dr. Dipanjan Chowdhury

Dr. Dipanjan Chowdhury is the Chief of the Division of Radiation and Genomic Stability at Dana-Farber and Co-Director of the new Center for BRCA and Related Genes (CBRG). Dr. Chowdhury is currently leading an exciting new protocol called “The MiDe Study” which uses a novel blood test aimed at early detection for ovarian cancer.

Dr. Pedro Ramirez

Dr. Pedro T. Ramirez is Chair of the Department of Obstetrics and Gynecologic at Houston Methodist Hospital and Professor at Weill Cornell College of Medicine. He is also the recipient of the Alan L Kaplan, MD Chair in Obstetrics & Gynecology. He is the Editor for the textbook titled Principles of Gynecologic Oncology Surgery. Dr. Ramirez is also the Editor-in-Chief of the International Journal of Gynecological Cancer. Most recently, Dr. Ramirez was made member of the IDEAL Council at Oxford University in England. In this role, he collaborates with leaders in the field of surgical research on developing strategies to integrate innovative surgical tools to the standard of care practice in patients with gynecological cancers.